Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance

Huh, Warner K.; Ault, Kevin A.; Chelmow, David; Davey, Diane D.; Goulart, Robert A.; García, Francisco; Kinney, Walter; Massad, L. Stewart; Ej, Mayeaux; Saslow, Debbie; Schiffman, Mark; Wentzensen, Nicolas; Lawson, Herschel W.; Einstein, Mark H.

doi:10.1016/j.ygyno.2014.12.022

Cited by 485 publications

(617 citation statements)

References 22 publications

Supporting

Mentioning

581

Contrasting

Unclassified

Order By: Relevance

“…Most HPV infections clear and so HPV testing also detects many more women who are not at risk for CIN2/3. This is part of the reason that in 2011 some organisations in the USA recommended cervical screening based on cytology in combination with hrHPV testing [7]. More recent evidence has suggested that hrHPV testing alone might be used as a primary screening test, with cytology reserved as a triage test [21].…”

Section: Introductionmentioning

confidence: 99%

HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier

Brentnall¹,

Vasiljević²,

Scibior‐Bentkowska³

et al. 2015

CBM

View full text Add to dashboard Cite

Abstract. BACKGROUND: Persistent infection with high risk human papillomavirus (hrHPV) types causes cervical cancer but most women who test positive are at very low risk of neoplasia. Strategies are needed which can retain high sensitivity of hrHPV testing but reduce the number of false-positives. We showed previously that a combination DNA methylation triage assay for HPV types 16, 18 and 31 and human gene EPB41L3 was useful to identify high grade cervical lesions. OBJECTIVE: Assess whether measurement of DNA methylation in HPV type 33 can improve the previous classifier. METHODS: A London colposcopy referral group of 1493 women of whom 556 (37%) had histologically-confirmed CIN (cervical intraepithelial neoplasia) 2 or 3 that included 114 HPV33 positive women with methylation measured for three L2 CpGs 5557, 5560 and 5566. Discrimination performance was assessed for the new classifier S5, built by adding HPV33 to the earlier classifier. RESULTS: HPV33 methylation measurement improved prediction among HPV33 positive women. Receiver operating characteristic analyses showed an area under the curve (AUC) for HPV33 methylation of 0.68 (95% CI 0.57-0.78). The earlier risk score was significantly improved by HPV33 methytlation (AUC = 0.82 vs 0.80; P < 0.001). For 90% sensitivity the specificity for CIN2/3 was 49% (95% CI 46-52%). CONCLUSIONS: Measurement of HPV33 DNA methylation contributes independent diagnostic information to EPB41L3 and HPV16, HPV18 and HPV31, and is superior to genotyping. Other HPV and human methylation target regions might be useful to further improve S5.

show abstract

Section: Introductionmentioning

confidence: 99%

HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier

Brentnall¹,

Vasiljević²,

Scibior‐Bentkowska³

et al. 2015

CBM

View full text Add to dashboard Cite

show abstract

“…Patients with positive test results for HPV 16/18 would undergo a colposcopy (20). It is strongly recommended that screening as well as vaccination against HPV, especially for high school girls, be included in the national immunization program.…”

Section: Discussionmentioning

confidence: 99%

The Most Frequent HPV Genotypes in Women with Cervical Cancer in Southwest of Iran

et al. 2018

View full text Add to dashboard Cite

Background: Cervical cancer ranked as the most common cancer of women in developing countries. Human Papillomaviruses (HPVs) belongs to the Papillomaviridea family, which is able to infect humans. Some HPV types are the causes of getting cervix cancer and it is clear that persistent infection, with a high -risk HPV genotypes, is known to be a major carcinogenic factor. Objectives: Determining the HPV genotypes distribution in women with cervical cancer in Khuzestan province, which is located in the southwest of Iran, to help design better preventive and also therapeutic strategies for promoting women health. Methods: A total of 75 archival cervical carcinoma tissue samples were studied for the presence of HPV DNA and determination of the genotypes by PCR and Sequencing. Genomic DNA was extracted from the FFPE cervical tissues and then subjected for the PCR based amplification with subsequent direct sequencing of the HPV positive PCR products. Results: The mean age of patients was 56. There were 42 samples with HPV DNA by using GP5+ and GP6+ primers. The result of HPV genotyping have been distinguished as follow: 33 samples as HPV-16, 4 samples as HPV-18, 1 sample for each HPV-54, 56 and 58 genotypes, and 2 samples remained unknown. Conclusions: Detecting HPV genotypes absolutely shed light on guidelines cervical cancer screening and vaccination policy in our country and in other developing countries. Collectively, our results suggest that HPV-16 is the frequent high -risk HPV type in our geographical area. HPV genotype testing, as a primary screening tool, plays an important role in cervical cancer prevention and therefore, it is a strongly recommended vaccination against HPV, especially for high school girls be included in the national immunization program.

show abstract

“…19 These guidelines suggest that (1) hrHPV screening may be considered as an alternative to a cytology-based screening strategy, (2) hrHPV screening should begin no earlier than age 25 and no sooner than 3 years after the last normal cytology test, and (3) re-testing after a negative primary hrHPV screen should occur no sooner than 3 years. For performing hrHPV screening, only an HPV assay approved for primary screening should be used (only the Roche cobas HPV Test is FDA-approved); performance characteristics vary among the four available tests, and thus they cannot be used interchangeably at this time.…”

Section: Hpv and Cervical Cancer Screeningmentioning

confidence: 99%

HPV Update: Vaccination, Screening, and Associated Disease

et al. 2016

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection is the causative agent in cervical cancer, and is associated with numerous other genital cancers, including vulvar, vaginal, and anal cancer. Primary prevention with HPV vaccination is safe and efficacious, and a recently approved HPV vaccine will provide even more extensive protection against several oncogenic HPV strains. Screening strategies for HPV are rapidly evolving, reflecting the essential role that HPV infection plays in cervical cancer. This article highlights new evidence regarding the efficacy of the recently approved 9-valent HPV (9vHPV) vaccine and the use of primary high-risk HPV testing in cervical cancer screening. We consider the utility of urinary HPV testing in routine clinical practice and review current guidelines regarding anal HPV screening.

show abstract

Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance

Cited by 485 publications

References 22 publications

HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier

HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier

The Most Frequent HPV Genotypes in Women with Cervical Cancer in Southwest of Iran

HPV Update: Vaccination, Screening, and Associated Disease

Contact Info

Product

Resources

About